8-K 1 dorearnings3q04.htm DOR EARNINGS 3Q-04 DOR EARNINGS 3Q-04

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):    November 15, 2004    


DOR BioPharma, Inc.
(Exact Name of Registrant as Specified in Charter)


 Delaware
  1-14778
 41-1505029
 (State or Other Jurisdiction of Incorporation)
 (Commission File Number)
  (IRS Employer Identification No.)
 
 Lincoln Building, 1691 Michigan Avenue Miami, FL 33139       
                                                   (Address of Principal Executive Offices)  (Zip Code)


Registrant’s telephone number, including area code (305) 534-3383
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
Item 2.02. Results of Operations and Financial Condition.
 
         On November 15, 2004, DOR BioPharma, Inc. issued a press release announcing its results of operations for the third quarter of 2004. A copy of the press release is attached as Exhibit 99 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
 
Item 9.01.  Financial Statements and Exhibits.
 
(c) Exhibits.

Exhibit No.    Title
 
99.1     Press release issued by DOR BioPharma, Inc. on November 15, 2004.
 



                                        SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                       DOR BIOPHARMA, INC.
                                        By: /s/ Evan Myrianthopoulos          
                                        President and Acting Chief Executive Officer
 
EXHIBIT INDEX

Exhibit            Description
 
99.1            Press release issued by DOR BioPharma, Inc. on November 15, 2004.